← back to picks
Founded 1880 · Mannheim Reporting EUR Credit S&P BBB- · synth Aa2/AA Valuation 2026-05-25 Damodaran FCFF · 1000-iter MC FCFF · Dark v3

Deep undervaluation, post β-triangulation · +131.7% margin of safety

Market far outside MC distribution — P(below) = 0%

Intrinsic value €205.84/share (after a 5% governance discount; pre-haircut €216.68) vs market €88.85. The Monte Carlo p5 tail still sits at €167 — every single one of 1,000 correlated stress draws lands above today's price.

p5 €167 p25 €191 p50 €212 p75 €236 p95 €269 MARKET €89 DCF €206
SectorEngineering / industrial servicesCountry mixDE 18% · UK 16% · NL 13%β / MC σ0.58 levered · ±€31/sh (1000 runs)GovernanceNo controlling holder · 5% haircutQualityROIC 13-15% · S&P BBB- · net-cash €146MDrawdown−17% from 2025 peak €107
Intrinsic / share
€205.84
post 5% gov · pre €216.68
Market / share
€88.85
14 May 2026 close · MDAX
Margin of safety
+131.7%
vs intrinsic
Enterprise value
€8.07B
80.8% terminal
Cost of equity / debt
5.12% / 2.07%
β 0.58 · CRP 0.47%
Terminal ROIC / g
14.70% / 2.50%
spread ~1003bp (ROIC 14.70% vs WACC 4.67%)

What it sells, where it sells

Operating segments

€5.43B FY25 revenue
E&M EuropeProcess plants, chemicals, energy — DACH + Benelux + Nordic core~64%
E&M InternationalUK North Sea O&G, US, Middle East — higher growth, lumpier margins~22%
TechnologiesEngineered specialties — best margin, growth-leveraged to energy transition~14%

Technologies (~14% of revenue) and the European base together carry the margin story; International is the growth pipeline where Mission 2030's “bigger acquisitions” — including the April 2026 Teknokon close — have to land for the 8% bull case to materialise.

Country mix (revenue-weighted CRP input)

🇩🇪Germany18%
🇬🇧United Kingdom16%
🇳🇱Netherlands13%
🇸🇪Sweden10%
🇺🇸United States10%
🇳🇴Norway8%
🇧🇪Belgium6%
🇿🇦South Africa4%
🇦🇹Austria4%
🌍Other (DK/PL/FI/Gulf/TR)11%

DE + UK + NL + SE + NO + BE + AT ≈ 75% of revenue — a Northern-European industrial-capex slowdown hits Bilfinger harder than the global E&C median. The South Africa (4%) and Turkey (1%) tails carry the EM CRP.

Background — five things to know before the case

Context the share price doesn't carry on its face. Skim this once and the bull / bear bullets below stop reading as inside baseball.

Where we diverge from the sector

Each row asks: if we'd used the sector median for this one assumption instead of our override, how much would the share price change? Negative = our override is more conservative (worth less); positive = more aggressive (worth more). Skim down the rightmost column to see which bets are doing the work.

Assumption
Our input
Sector median
Value impact
01Revenue growth10-year revenue CAGR vs Engineering/Construction median
~5.6% CAGR7% Y1-5 fading to 2.5% terminal — backlog + Stork synergies, no unconfirmed M&A
~4.5% CAGREngineering/Construction, global cross-sector median
+€18
02Operating marginYear-5 EBITA target vs sector median EBIT margin
7.0%Peer +50bps; Mission 2030 mid-point is 8.5% (in bull case)
6.5%Engineering/Construction sector median, 48-firm cohort
+€10
03Sales-to-capitalReinvestment efficiency Y1-5 vs sector median
3.5×Current implied 3.9× fading as M&A goodwill absorbs capital
4.36×Engineering/Construction industry standard
−€8
04Terminal growthYear 10+ steady state vs EUR risk-free ceiling
2.50%Council edit from 3.5% — Bund-anchored for a DE-heavy book
2.40%Engine-resolved EUR-blended government-bond yield
+€2
05Cost of capital10y WACC vs WACC implied by sector-median β
4.67%β 0.58 (5Y market regression, multi-source: StockAnalysis 0.55, SimplyWallSt 0.58, FT 0.59) · CRP 0.47% · D/V ~15%
~5.76%Damodaran global Eng/Construction β_u 0.76 re-levered → β_lev 0.85 — triangulation triggered (47% gap vs regression), regression won
+€14
Net effect of overrides
Overrides net +€55/share vs all-defaults — modestly aggressive on growth and margin and now also on WACC (5Y regression β 0.58 beats both Damodaran global re-levered 0.85 and the 48-firm US-only cohort 1.28 at multi-source corroboration), partly offset by a fading S2C that bakes in known M&A goodwill absorption.
+€55
Our override Sector median Override adds value Override subtracts value

The story & the five claims

The 10-year story this DCF is built on, plus the five anchor claims that translate the story into DCF inputs.

The 10-year story

Bilfinger is the post-restructuring industrial-services compounder that Cevian Capital fixed and is now exiting. Under Thomas Schulz (CEO since 2022) the company has rebuilt a structurally lighter, higher-margin business serving Continental European process industries — EBITA went from a €221m loss in 2020 to a €299m profit in 2025 on roughly flat capital. The base case isn't that Mission 2030 lands in full — that's the bull case. It's that the announced backlog plus organic European industrial-services growth delivers 7% revenue compounding through 2030, fading to a Bund-anchored 2.5% terminal, with EBITA margin maturing to 7.0% (a peer-plus-50bps outcome, not peer-plus-100bps). Revenue compounds from €5.4B today to €9.4B by 2035; operating margin re-anchors at 7.0% from year 5; terminal growth pinned at 2.5%.

Two debates worth pressure-testing

Does the Iran/Q1 order-book wobble flag a real cycle roll?
Our view: No — March was acknowledged as “unusually quiet for decision-making”, FY26 guidance reaffirmed (rev €5.4–5.9B, EBITA 5.8–6.2%), and insiders bought on the same-day sell-off. If we're wrong and the cycle rolls, the bear scenario (4-5% margin, no M&A) implies ~€110/share — still above today's €88.85.
Should we model Mission 2030 in full (8% growth, 8.5% margin)?
Our view: No — that's the bull case (30% probability, ~€220/share in scenarios.yaml). The base anchors on Mission 2030's lower bound plus organic, because the “bigger international acquisitions” required for full delivery have not yet closed. Probability-weighted PT lands around €180.
CLAIM 01Revenue compounds 7% Y1-5, fading to 2.5% terminal.growth_high: 7.0% · terminal: 2.5% · €5.4B → €9.4BMid-point between organic European industrial-services rate (~4%) and the lower bound of Mission 2030's 8% CMD band. Excludes unconfirmed M&A.
CLAIM 02EBITA margin matures to 7.0% by 2030 and holds.target_op_margin: 7.0% from Y55.7% (2025) → 7.0% (2030) via mix shift to biopharma + energy transition specialty work. Peer +50bps, not peer +100bps — pricing in 5y discipline without overpaying for full Mission 2030.
CLAIM 03Capital efficiency fades modestly as M&A absorbs goodwill.S2C: 3.5× Y1-5 · 3.0× Y6-10Current implied 3.9× fades on disclosed M&A pipeline; even at 3.0× the year-10 ROIC = 14.70%, comfortably above 4.67% WACC.
CLAIM 04Margin converges by Y5; growth by Y10.year_of_convergence: 5 (= 2030)Aligns with Mission 2030's 2030 finish line. No further margin expansion in years 6–10; growth fades linearly to terminal.
CLAIM 05No failure risk — IG balance sheet, net-cash, no distress tail.terminal_g: 2.50% · failure: 0% · gov haircut: 5%S&P BBB-, +€146m net liquidity, FCF €600–700m cumulative 2021–25. 5% governance haircut for residual M&A acceleration + Turkey exposure (Teknokon close).
Where we diverge from sell-side
  • Terminal growth pulled to 2.5%, not 3.5%. Bund-anchored for a 75%-Northern-European book — cannot exceed the EUR-blended risk-free of 2.40% without a diagnostic firing. Sell-side anchors on the higher CMD framing.
  • Margin target capped at 7.0%, not 8.5%. Peer +50bps reflects 5y of post-Schulz discipline without pricing in full Mission 2030 delivery. Full 8.5% lives in the scenarios.yaml bull (30% probability, ~€220/share).
  • Governance haircut 5%, against the council's 7.5% suggestion. Trades on the Schulz-era track record (clean compliance, declining share count, insider buying on the dip) and accepts forward M&A-acceleration + Turkey tail risk as a small drag, not a structural one.
  • Base year is FY25 reported, not FY26 guide midpoint. Capital employed of €1.93B, EBITA of €299m, S2C of ~3.9× — anchors on what filed, not on a guided number that bakes in the Q2-Q3 FCF recovery management is forecasting.
  • WACC re-corrected via β triangulation. Earlier pass used Damodaran's US Eng/Construction subset (β_u 1.14, β_lev 1.28), giving WACC 7.45%. A correction to global (β_u 0.76, β_lev 0.85) gave WACC 5.76%, but the multi-source 5Y regression β for GBF is 0.58 (StockAnalysis, SimplyWallSt, FT all between 0.55 and 0.59). The 47% gap between regression and Damodaran-global triggers triangulation → trust regression. Bilfinger's industrial-services recurring-contract model has structurally lower market covariance than the broad Eng/Construction aggregate. Final: β 0.58, Ke 5.12%, WACC 4.67%, MoS +131.7%.
    • Two-sided case — bear anchors
    • Process-industry cycle rolls 2027-28. European chemicals overcapacity persists, energy-transition capex slips. Margin reverts toward 4–5%, M&A doesn't materialise. Bear scenario in scenarios.yaml lands ~€110/share — still above today's €88.85 but a 36% drawdown from base.
    • Mission 2030 M&A accident. “Bigger international acquisitions” deploy goodwill that doesn't earn its cost of capital. Adds ~7pp governance penalty, S2C compresses below 3.0×, year-10 ROIC drops to 10–11%. ~€50–60/share equity drag.
    • Turkey exposure proves harder than priced. Teknokon (closed 1 Apr 2026) brings idiosyncratic political/FX risk that the 1% revenue weight under-captures. If Turkey CRP jumps from 3.06% to 5–6% on a stress, weighted CRP doubles → WACC +30bps → ~€10/share off.
    • UK offshore strike action escalates. The Ithaca Energy Alba FSU/FPF dispute is small (~20 workers, retention bonus) but headline risk in a 16%-of-revenue UK book. Realistically a 1-2% margin drag for a quarter, not a thesis-breaker.
    • Cevian board oversight gap. Two Cevian partners (Dr. Cordes — Chairman, Schuchna) still on the Supervisory Board, but if/when they exit, monitoring intensity drops. Historical pre-Cevian Bilfinger ran serial profit warnings — culture risk re-emerges, not balance-sheet risk.

    Risks to thesis (tail, not bear case)

    Process-industry capex trough Med

    European chemicals overcapacity + LNG buildout slippage compresses margin by 2-3pp for 2027-28. ~15-20% equity drag, doesn't break the thesis but rolls the recovery.

    Mission 2030 M&A accident High

    A “bigger international” deal that doesn't earn its cost of capital. CFO has flagged appetite; track record under Schulz is 4 years of clean bolt-ons but no transformative tests. ~€50/share drag if it goes wrong.

    Turkey / Teknokon FX + political Med

    Lira volatility + Mid-East geopolitical contagion. 1% revenue weight under-captures the idiosyncratic risk. Stress: Turkey CRP from 3.06% to 5-6% → ~€10/share off.

    Iran-conflict order delay persists Med

    If “unusually quiet” March extends into H2 2026, FY26 guide slips and the 2025 share-price re-rating reverses. Cyclical, not structural — but headline risk for 12-18 months.

    Legacy culture tail Low

    2014–2020 corruption probes and serial profit warnings sit in the past, but if Cevian board representation fully exits the monitoring premium erodes. Tail risk, not base case.

    UK offshore strike escalation Low

    Ithaca Alba FSU/FPF dispute (~20 workers). Small absolute size in a 16%-of-revenue UK book. 1-2% margin drag for a quarter, max.

    10-year forecast

    Revenue €5.81B → €9.39B over 10y (7% Y1-5 organic + announced backlog, fading to 2.5% terminal). Operating margin lifts from 5.6% Y1 to 7.0% by Y5 (Mission 2030 finish line) and holds — peer +50bps, not peer +100bps.

    Y1 Y2 Y3 Y4 Y5 Y6 Y7 Y8 Y9 Y10 0 9.4B rev (EUR) 0% 10% op margin revenue FCFF op margin

    Monte Carlo distribution

    Even at the 5th-percentile outcome (€167), intrinsic value exceeds today's €88.85 price by 87% — the disagreement isn't whether Bilfinger is undervalued, but by how much.

    market 88.85 79.9 200.4 320.8 freq equity / share (EUR)

    Mean €214.36 ± €31.24/sh, 1000 iterations (0 failed). P(intrinsic < market €88.85) = 0.0% — undervaluation is robust to the joint distribution of sampled inputs.

    ⚠ Active diagnostic: terminal_growth (0.0250) >= risk_free_rate (0.0240); Damodaran's stable-growth ceiling is the risk-free rate. Council had already lowered terminal_growth from 3.5% to 2.5%; the 10bp gap above the EUR-blended risk-free (2.40%) sits well inside Monte-Carlo noise (σ €31/sh on a €212 base).
    Cost of capital build
    Risk-free rate 2.40%
    Mature-market ERP 4.10%
    Levered β 0.58
    Weighted CRP 0.47%
    Cost of equity 5.12%
    Pre-tax cost of debt (synth Aa2/AA) 2.95%
    D / V ~15%
    WACC 4.67%
    Full year-by-year DCF
    Year Revenue Op mgn EBIT EBIT(1−t) Reinvest FCFF PV
    1 €5.81B 5.60% €325M €235M €109M €126M €120M
    2 €6.21B 5.95% €370M €267M €116M €150M €137M
    3 €6.65B 6.30% €419M €302M €124M €178M €155M
    4 €7.11B 6.65% €473M €341M €133M €208M €173M
    5 €7.61B 7.00% €533M €384M €142M €242M €193M
    6 €8.08B 7.00% €565M €405M €155M €250M €190M
    7 €8.50B 7.00% €595M €424M €140M €284M €204M
    8 €8.86B 7.00% €620M €439M €122M €318M €216M
    9 €9.16B 7.00% €641M €452M €100M €351M €226M
    10 €9.39B 7.00% €657M €460M €76M €384M €232M
    Methodology & flags

    Damodaran FCFF DCF, 10y explicit + perpetuity. R&D not capitalised (industrial services; no separate disclosure). IFRS-16 leases already in book debt. Synth credit Aa2/AA. CRP from 16-country revenue-weighted Damodaran 2026 CRPs (Germany 18%, UK 16%, NL 13%, SE 10%, others). Monte Carlo: 1000 iterations with correlated draws on growth, margin, S2C, terminal-g, and CoC. Engine v1.0.0 · result: /Users/valentin/Documents/notes_jiliac_labs/Finance/Damodaran/valuations/gbf/output/2026-05-25-result.json

    • R&D cap: OFF · Lease cap: OFF · Failure: OFF · ESO: OFF
    • Governance haircut: 5% applied post-DCF (€216.68 pre > €205.84 post)
    • Sensitivity tornado: not run (MC supersedes — 1000 correlated draws)